Compugen Ltd. (NASDAQ:CGEN)‘s stock had its “buy” rating restated by equities researchers at FBR & Co in a report issued on Tuesday.

Separately, Zacks Investment Research upgraded Compugen from a “sell” rating to a “hold” rating in a research report on Tuesday, August 2nd. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $10.40.

Analyst Recommendations for Compugen (NASDAQ:CGEN)

Compugen (NASDAQ:CGEN) opened at 6.65 on Tuesday. Compugen has a 1-year low of $4.32 and a 1-year high of $7.79. The firm has a 50-day moving average price of $6.13 and a 200-day moving average price of $6.60. The company’s market capitalization is $338.66 million.

Compugen (NASDAQ:CGEN) last announced its earnings results on Monday, November 7th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.01. Compugen had a negative net margin of 261.77% and a negative return on equity of 29.33%. On average, analysts forecast that Compugen will post ($0.61) EPS for the current fiscal year.

Several hedge funds have recently modified their holdings of CGEN. Geode Capital Management LLC increased its stake in shares of Compugen by 20.9% in the first quarter. Geode Capital Management LLC now owns 22,873 shares of the company’s stock valued at $127,000 after buying an additional 3,959 shares during the period. Benjamin F. Edwards & Company Inc. bought a new stake in shares of Compugen during the second quarter valued at approximately $164,000. D. E. Shaw & Co. Inc. increased its stake in shares of Compugen by 17.6% in the third quarter. D. E. Shaw & Co. Inc. now owns 31,197 shares of the company’s stock valued at $197,000 after buying an additional 4,671 shares during the period. ProShare Advisors LLC increased its stake in shares of Compugen by 0.8% in the second quarter. ProShare Advisors LLC now owns 37,652 shares of the company’s stock valued at $244,000 after buying an additional 300 shares during the period. Finally, Janney Montgomery Scott LLC increased its stake in shares of Compugen by 2.2% in the second quarter. Janney Montgomery Scott LLC now owns 45,787 shares of the company’s stock valued at $293,000 after buying an additional 1,000 shares during the period. 14.36% of the stock is owned by hedge funds and other institutional investors.

About Compugen

Compugen Ltd. (Compugen) is a therapeutic discovery company. The Company focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins in the fields of oncology and immunology. Its pipeline program consists of drug targets and therapeutic product candidates at various stages ranging from target validation to pre-clinical studies in the fields of oncology and immunology, with a primary focus on immuno-oncology.

5 Day Chart for NASDAQ:CGEN

Receive News & Stock Ratings for Compugen Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen Ltd. and related stocks with our FREE daily email newsletter.